- Veradigm, a division of Allscripts focused on payers and life sciences, has entered into an agreement with Microsoft to connect patients with clinical studies through the cloud-based Allscripts EHR system, the Chicago-based company announced.
“By integrating research at the point of care, we have the potential to lower costs, increase efficiencies, and remove bottlenecks that inhibit research, all while improving the welfare of patients,” said Veradigm CEO Tom Langan. “The barriers preventing this shift have now largely been removed – what is needed is a commitment to developing the technologies, workflows, processes and compliance frameworks to support it.”
The impetus for the partnership is the ability to support clinical research while delivering patient care.
“The initial focus of this collaboration will be to extend Allscripts’ cloud-based electronic health record (EHR) platforms with innovative technologies focused on enabling integrated research — for instance point-of-care, automated ‘match-making’ between study protocols and the patients and providers who may qualify for those studies,” the announcement stated.
Forthcoming pilot programs are likely to contribute to a new understanding of the workflows necessary to support such an effort, and the cloud is critical to the nature of the project which just so happens to be an area where Microsoft continues to expand its presence with Azure.
“New technologies and models have the potential to drastically improve the clinical research process,” added Microsoft VP of US Health and Life Sciences Chris Sakalosky. “Working alongside industry leaders like Veradigm, we believe solutions powered by Microsoft Azure and AI will help biopharmaceutical and clinical research organizations better conduct research, and, in the future, improve quality of life.”
“Just as rideshare organizations such as Lyft replaced the traditional specialized taxi driver and dispatch service with technology enabled drivers, we envision a network of technology enabled research clinicians providing an alternative to the roles associated within the traditional clinical trial operating model,” Veradigm VP & GM Stephanie Reisinger observed.
In the announcement, Allscripts called attention to recent guidance the Food and Drug Administration released in 2018 around the use of real EHR data in clinical investigations.
The EHR company has demonstrated a serious commitment to leveraging artificial intelligence as a means of supporting improvements to care delivery as well as laying the foundation for future innovations around health IT.
“We now have a platform that is virtually all digital, and it is generating all sorts of valuable information for us that can be analyzed and leveraged in multiple ways,” Allscripts CEO Paul Black told HealthITAnalytics.com last May.
“Unfortunately, we know that much of that data is being created across multiple venues in many different formats, which creates a lot of challenges that have become very familiar to the industry in recent years.”
Top of mind at the time was attacking provider EHR dissatisfaction head-on. But the EHR company’s approach to its software has the added benefit of creating new opportunities for development enabled by cloud computing.
Elsewhere in health IT
A former Allscripts executive has found a landing spot alongside to a former competitor.
Digital health company Livongo Health recently named Lee Shapiro to the position of chief financial officer. Shapiro joins forces with the former head of Allscripts and Livongo Executive Chairman Glen Tullman and former Cerner President and Livongo CEO Zane Burke.
“I couldn’t be more excited about working with Lee,” said the latter. “His intimate knowledge of Livongo, his close working relationships with the leadership team, and his connections across the industry, including virtually every analyst in the healthcare and technology space, will allow us to rapidly accelerate our business and better serve our members and clients.”
The sale of athenahealth is the subject of another investigation, this time by law firm Levi & Korsinsky, LLP. The New York-based firm will review the fairness of the sale of the health IT company to Veritas Capital and Evergreen Coast Capital at $5.7 billion ($135 per share). Rigrodsky & Long, PA, has already initiated legal proceedings against athenahealth et al. in the District Court of Delaware